AZD1152 in Patients With Advanced Solid Malignancies-Study 1

A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2 Hour Intravenous Infusion on Two Dose Schedules in Patients With Advanced Solid Malignancies

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00497731

Enrollment

Registered

2007-07-09

Start date

2005-05-31

Completion date

2009-04-30

Last updated

2009-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

Keywords

Advanced solid tumors

Brief summary

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 2-hour infusion every week and every 2 weeks in patients with advanced solid malignancies.

Interventions

DRUGAZD1152

2-hour continuous intravenous infusion

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histological or cytological confirmation of a solid, malignant tumour * At least measurable or non measurable site of disease as defined by modified RECIST criteria.

Exclusion criteria

* Participation in an investigational drug study within 30 days prior to entry or who have not recovered from the effects of an investigational study drug * Treatment with radiotherapy/chemotherapy with 4 weeks of first dose * Recent major surgery within 4 weeks prior to entry to the study

Design outcomes

Primary

Measure	Time frame
Safety and Tolerability	Assessed at each visit

Secondary

Measure	Time frame
Pharmacokinetics	Assessed at predetermined timepoints after dose administration
Effect on biomarkers	Assessed after treatment
Anti-tumor activity	Assessed after treatment

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026